Company: NYXH
Filing Date: 2025-11-14
Form Type: 6-K
Source: 0001104659-25-111616
Chunk: 1

Company: Nyxoah SA
Filing Date: 2025-11-14
Form: 6-K
Chunk 1
---
“Private Placement”) of ordinary shares, no nominal value per share of the Company (the “Ordinary Shares”), at
a price per share of €4.00, for aggregate gross proceeds of approximately €17.0 million. The closing of the Private Placement is
expected to occur on or about November 18, 2025, subject to customary closing conditions.

The Company expects to use the proceeds from the Private Placement(i) to launch commercialization activities in the United
States and advance the commercialization of the Genio system in its initial target markets outside the United States; (ii) to continue
gathering clinical data and to support physician-initiated clinical research projects related to obstructive sleep apnoea (“OSA”)
patient treatments; (iii) to further finance research and development activities related to Genio system upgrades, re-designing our products
for manufacturability and cost reduction initiatives; (iv) to continue to build a pipeline of new technologies and explore potential collaboration
opportunities in the field of monitoring and diagnostics for OSA; and (v) for other general corporate purposes, including, but not limited
to, working capital, capital expenditures, investments, acquisitions, should the Company choose to pursue any, and collaborations.

The form of Subscription Agreement will be filed
as an exhibit to a future filing and the foregoing description of the terms of the Subscription Agreements is qualified in
its entirety by reference to such exhibit.

This Current Report shall not constitute an offer
to sell or the solicitation to buy nor shall there be any sale of the Company’s securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state
or jurisdiction.

The ordinary shares issued and sold in the Private
Placement are not being registered under the Securities Act of 1933, as amended (the “Securities Act”). Certain of the ordinary
shares are being offered in a private placement to non-U.S. Persons (as such term is defined under Rule 902 of Regulation S under the
Securities Act (“Regulation S”)) in a transaction outside the United States pursuant to Regulation S. The remaining ordinary
shares are being offered in a private placement to U.S. Persons (as such term is defined under Rule 902 of Regulation S) pursuant to the
exemption provided in Section 4(a)(2) of the Securities Act. Each U.S. investor is an “accredited investor” (as